Telomir Pharmaceuticals, Inc | WebDisclosure

Basculer en Français

11302	Companies
251207	Keywords
180268	Articles
137071	Press releases

Headlines Articles Press releases Telomir Pharmaceuticals, Inc

Home
Companies
Telomir Pharmaceuticals, Inc

PRESS RELEASE

published on 10/09/2025 at 13:30, 1 year 1 month ago

Telomir Pharmaceuticals Reports Discovery That Telomir-1 Selectively Kills Aggressive Triple-Negative Breast Cancer Cells
Telomir Pharmaceuticals announces new findings showing Telomir-1's impact on aggressive breast cancer cells, targeting iron-dependent regulation and cellular energy pathways

Telomir-1 Telomir Pharmaceuticals Breast Cancer Cells Iron-dependent Regulation Cellular Energy Pathways
BRIEF

published on 10/07/2025 at 13:35, 1 year 1 month ago

Telomir Pharmaceuticals dévoile des résultats précliniques prometteurs dans le traitement du cancer de la prostate

Cancer De La Prostate Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Suppresseurs De Tumeurs
BRIEF

published on 10/07/2025 at 13:35, 1 year 1 month ago

Telomir Pharmaceuticals Unveils Promising Preclinical Results in Prostate Cancer Therapy

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Tumor Suppressors
PRESS RELEASE

published on 10/07/2025 at 13:30, 1 year 1 month ago

Telomir Pharmaceuticals Announces New Findings in a Prostate Cancer Model Demonstrating Telomir-1 Also Resets DNA Methylation of Tumor Suppressor Genes Implicated in Two of the Most Persistent Challenges in Oncology-Metastasis and Treatment Resistance
Telomir Pharmaceuticals unveils new preclinical findings showing Telomir-1 reactivates tumor suppressor genes MASPIN and RASSF1A in aggressive prostate cancer models, offering potential for improved chemotherapy response and metastasis control

Prostate Cancer Telomir-1 Telomir Pharmaceuticals Preclinical Findings Tumor Suppressor Genes
BRIEF

published on 09/18/2025 at 14:05, 1 year 1 month ago

Telomir-1 Shows Expanded Targeting of Histone Demethylases

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy Histone Demethylases Cancer And Aging
BRIEF

published on 09/18/2025 at 14:05, 1 year 1 month ago

Telomir-1 montre un ciblage élargi des déméthylases d'histones

Telomir-1 Telomir Pharmaceuticals Thérapie Épigénétique Histone Demethylases Cancer Et Vieillissement
PRESS RELEASE

published on 09/18/2025 at 14:00, 1 year 1 month ago

Telomir Pharmaceuticals Announces In Vitro Data Showing Telomir-1 Targets Additional Histone Demethylase Families, a Unique Profile in Cancer and Aging Not Seen in Other Therapies
Telomir Pharmaceuticals announces Telomir-1's new in vitro results inhibiting KDM5 family, expanding epigenetic therapy possibilities in cancer treatment and aging slowdown

Telomir-1 Telomir Pharmaceuticals Epigenetic Therapy KDM5 Family Inhibition Cancer Aging Treatment
BRIEF

published on 09/09/2025 at 14:05, 1 year 2 months ago

Telomir Pharmaceuticals Unveils Promising Preclinical Cancer Data

Cancer Research Telomir-1 Telomir Pharmaceuticals DNA Methylation CDKN2A
BRIEF

published on 09/09/2025 at 14:05, 1 year 2 months ago

Telomir Pharmaceuticals dévoile des données précliniques prometteuses sur le cancer

Telomir-1 Telomir Pharmaceuticals Recherche Sur Le Cancer Méthylation De L'ADN CDKN2A
PRESS RELEASE

published on 09/09/2025 at 14:00, 1 year 2 months ago

Telomir Pharmaceuticals Announces New Cancer Data in Aggressive Human Prostate Cancer Cells Showing Telomir-1 Resets DNA Methylation to Reactivate CDKN2A, a Master Tumor Suppressor, Outperforming Rapamycin and Chemotherapy
Telomir Pharmaceuticals announces new preclinical findings showing Telomir-1's ability to reverse CDKN2A gene silencing by DNA methylation, potentially restoring cancer cell cycle control and immune surveillance

Cancer Therapy Telomir Pharmaceuticals Preclinical Findings DNA Methylation CDKN2A Gene

Accesswire

Published on 11/10/2026 at 08:00, 51 minutes ago

PEL 82 - QatarEnergy to Acquire 25% Participating Interest from Chevron
Published on 11/10/2026 at 02:45, 6 hours 6 minutes ago

Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 9 hours 41 minutes ago

Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 9 hours 51 minutes ago

LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 10 hours 19 minutes ago

Announces Extension for Closing of Private Placement of Convertible Promissory Notes

View all ACCESSWIRE

EQS Group

Published on 11/10/2026 at 08:42, 8 minutes ago

KSB reports strong order intake in third quarter
Published on 11/10/2026 at 08:30, 21 minutes ago

Restoration - Notting Hill Genesis
Published on 11/10/2026 at 08:25, 25 minutes ago

ZPMC-Led Smart Port Machinery Alliance Reports Growing Industry Collaboration at Annual Meeting
Published on 11/10/2026 at 08:15, 35 minutes ago

EOS Holding - Gen Z and millennials: tech-savvy, financially under pressure
Published on 11/10/2026 at 08:10, 40 minutes ago

ANTHBOT Announces $250 / €250 Black Friday Discounts on M5 and M9 Robotic Lawn Mowers

Les Echos

Published on 11/10/2026 at 07:00, 1 hour 51 minutes ago

bioMérieux receives U.S. FDA 510(k) Clearance and IVDR CE marking for VITEK® PRO, its new automated ID/AST instrument to support the fight against antimicrobial resistance
Published on 11/10/2026 at 07:00, 1 hour 51 minutes ago

bioMérieux obtient l’autorisation 510(k) de la FDA américaine et le marquage CE selon l’IVDR pour VITEK® PRO, son nouvel instrument automatisé d’identification et d’antibiogramme contribuant à la lutte contre l’antibiorésistance
Published on 11/09/2026 at 18:30, 14 hours 21 minutes ago

Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 14 hours 21 minutes ago

Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
Published on 11/09/2026 at 17:45, 15 hours 6 minutes ago

Weekly share buyback

View all LES ECHOS COMFI WIRE